In prostate cancer, elevated levels of KLK2, 4 and 13–15 mRNA and/or protein have been reported; KLK3, 5, 7, 10 and 11 are decreased compared to nonmalignant tissue counterparts (Table 5, Figure 2). This evidence concerns the gene KLK3 and prostate carcinoma.